By Josh Beckerman
Shares of Candel Therapeutics fell to a 52-week low after the cancer-focused biopharmaceutical company reported interim data from a CAN-2409 clinical trial in non-metastatic pancreatic cancer.
Candel said “initial positive interim data revealed notable improvements in patients with borderline resectable pancreatic ductal adenorcarcinoma (PDAC) after experimental treatment with CAN-2409” in the phase 2 trial. It said a safety analysis demonstrated that multiple injections were generally well tolerated, with no reported dose-limiting toxicities and no cases of pancreatitis.
The stock was recently down 8%, to 79 cents, and had an intraday low of 66 cents. Volume was more than 233,000 shares, compared with a 65-day average of 20,067.
Write to Josh Beckerman at [email protected]
Read the full article here